Baton Rouge Xarelto Lawyers
Xarelto: Dangerous Blood Thinner
Xarelto (rivaroxaban) is part of a family of anticoagulants, known as “direct thrombin inhibitors,’ which are designed to reduce the threat of blood clots and strokes by thinning the blood. Xarelto was introduced in November 2011, as a joint venture by Bayer and Johnson & Johnson’s Janssen subsidiary, and it is on the path to becoming a blockbuster medication, with more than $1 billion in annual sales.
Bayer and Johnson & Johnson aggressively promoted Xarelto as a superior blood thinner to Coumadin (warfarin), which has been the standard anticoagulation therapy for years. The manufacturers represented that the drug is easier to use than warfarin, because patients do not need to be monitored regularly during treatment.
To stay up-to-date in Xarelto lawsuit news, visit our What’s New In Xarelto Litigation? Page, updated weekly.
The FDA initially approved Xarelto in July of 2011, to reduce the risk of blood clots, deep vein thrombosis (DVT) and pulmonary embolism following knee and hip surgery. In November of 2011, it was approved as an anti-coagulant for individuals with non-vascular atrial fibrillation.
In November of 2012, FDA approval was expanded to include patients with DVT and pulmonary embolism. Xarelto was approved as a long-term treatment to prevent recurrence of those conditions. Recent lawsuits allege that the Xarelto warnings fail to adequately disclose the risk of uncontrollable hemorrhages due to the lack of an approved antidote. Unlike warfarin, the blood thinning effects of Xarelto cannot be reversed in a critical situation like an auto accident or brain hemorrhage; often leaving doctors unable to control bleeding that may develop among users.
Xarelto was promoted as superior to warfarin because it is easier to take and requires less frequent monitoring to maintain the correct dosage. While all anticoagulants carry a risk of bleeding, warfarin’s blood thinning effect can be reversed with a combination of vitamin K and plasma. Because Xarelto does not have a reversal agent, it can be extremely difficult for doctors to stop bleeding events before serious injury or death occurs. Some doctors have had partial success with pro-thrombin complex concentrates (PCCs), but the FDA has not approved an official reversal agent or strategy to stop life-threatening bleeding events.
In September of 2013, the German newspaper Der Speigel reported that there had been approximately 1,000 adverse events involving Xarelto through the first of eight months of 2013 alone, including 72 deaths. In May of 2014, the Institute for Safe Medication Practices (ISMP) reported that doctors and patients were reporting adverse events linked to the use of Xarelto in increasing numbers. ISMP reported in Quarter Watch that there were 680 Xarelto adverse events reported in the U.S. in 2013. The number of adverse reports linked to Xarelto surpassed those attributed to the Pradaxa, which had once held the distinction of being the drug with the most adverse event reports to the FDA.
Murphy Law Firm, LLC is currently handling Xarelto lawsuits and is accepting more. Fill out our Xarelto questionnaire and call (800) 734-6545 to get prompt help with your claim.
Side Effects of Xarelto
The most common reported side effects of Xarelto are uncontrollable bleeding and severe internal bleeding. Other common complications include:
- Gastrointestinal Bleeding
- Rectal Bleeding
- Brain Hemorrhage
New Claims: Patients Weren’t Warned about Fatal Bleeding Risks
Defendants’ Xarelto package warning did not address the increased risk for serious and fatal bleeding.
Reuters has reported that Germany -based Bayer AG is facing its first lawsuits in the U.S. over Xarelto, which is among the company’s top selling medications. Those cases are being consolidated in the Eastern District of Louisiana. Visit our Xarelto MDL Updates page to see what’s new in consolidated Xarelto litigation.
According to Reuters, Xarelto made $1.3 billion in sales in 2013. Reports indicate that a Xarelto lawsuit was filed earlier this year on behalf of a Kentucky woman who alleged that she suffered severe internal bleeding after using the blood thinner.
According to the lawsuit, the Kentucky woman was prescribed Xarelto in July of 2012 to treat atrial fibrillation, and was hospitalized a half-year later with severe internal and gastrointestinal (GI) bleeding. The Xarelto lawsuit contends that Johnson & Johnson should not have sold the medication and should have known Xarelto was associated with “irreversible bleeds.”
The suit against Johnson & Johnson and Bayer AG was filed in the Pennsylvania Court of Common Pleas, Philadelphia County, on February of 2014. (Stuntebeck v. Janssen Research & Development LLC et al; Civil Action No.: 140201754)[reuters.com/article/2014/06/14/us-bayer-suit-idUSKBNoEPoHW20140614, June 14, 2014]
Learn More About Filing A Xarelto Lawsuit.
If you or someone you love has suffered serious side effects from Xarelto, such as severe bleeding, internal bleeding, blood clots, stroke or heart attack, you may be eligible to file a Xarelto lawsuit against the manufacturer of the blood thinner.
For more information on the legal options available to you and your family, or to file a Xarelto lawsuit, contact Murphy Law Firm, LLC by downloading and completing our online form or by calling us at (800) 734-6545.